PMC:7306567 / 4278-6564
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
67 | 243-247 | Disease | denotes | CL-F | OMIM:102510 |
68 | 255-274 | Disease | denotes | infectious diseases | MESH:D003141 |
69 | 372-374 | Disease | denotes | PD | MESH:D010300 |
70 | 394-396 | Disease | denotes | LV | MESH:C535509 |
71 | 588-612 | Disease | denotes | invasive fungal diseases | MESH:D000072742 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T36 | 255-265 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T25 | 191-197 | http://purl.obolibrary.org/obo/UBERON_0007688 | denotes | fields |
T26 | 243-245 | http://purl.obolibrary.org/obo/CLO_0052906 | denotes | CL |
T27 | 282-284 | http://purl.obolibrary.org/obo/PR_000010213 | denotes | MB |
T28 | 320-322 | http://purl.obolibrary.org/obo/CLO_0007706 | denotes | MH |
T29 | 383-385 | http://purl.obolibrary.org/obo/UBERON_0003064 | denotes | IM |
T30 | 432-434 | http://purl.obolibrary.org/obo/CLO_0008828 | denotes | RL |
T31 | 481-483 | http://purl.obolibrary.org/obo/CLO_0007029 | denotes | JM |
T32 | 481-483 | http://purl.obolibrary.org/obo/CLO_0050993 | denotes | JM |
T33 | 747-748 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T34 | 789-790 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T35 | 854-859 | http://purl.obolibrary.org/obo/UBERON_0007688 | denotes | field |
T36 | 974-975 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T37 | 1247-1248 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T38 | 1564-1566 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T39 | 1569-1570 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T40 | 1663-1664 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T41 | 1856-1857 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T42 | 1946-1947 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T43 | 1967-1976 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | organizer |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T18 | 239-241 | Chemical | denotes | KL | http://purl.obolibrary.org/obo/CHEBI_74561 |
T19 | 320-322 | Chemical | denotes | MH | http://purl.obolibrary.org/obo/CHEBI_74703 |
T20 | 354-362 | Chemical | denotes | medicine | http://purl.obolibrary.org/obo/CHEBI_23888 |
T21 | 364-366 | Chemical | denotes | EA | http://purl.obolibrary.org/obo/CHEBI_73849 |
T22 | 372-374 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T23 | 376-378 | Chemical | denotes | PW | http://purl.obolibrary.org/obo/CHEBI_74797 |
T24 | 379-381 | Chemical | denotes | LL | http://purl.obolibrary.org/obo/CHEBI_73531 |
T25 | 383-385 | Chemical | denotes | IM | http://purl.obolibrary.org/obo/CHEBI_74073 |
T26 | 394-396 | Chemical | denotes | LV | http://purl.obolibrary.org/obo/CHEBI_73579 |
T27 | 432-434 | Chemical | denotes | RL | http://purl.obolibrary.org/obo/CHEBI_73815 |
T28 | 481-483 | Chemical | denotes | JM | http://purl.obolibrary.org/obo/CHEBI_31739 |
T29 | 976-981 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T30 | 1034-1039 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T31 | 1167-1172 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 904-916 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
T3 | 1333-1341 | http://purl.obolibrary.org/obo/GO_0015297 | denotes | exchange |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T28 | 0-24 | Sentence | denotes | Participants and methods |
T29 | 25-124 | Sentence | denotes | The expert panel is comprised of 29 participants from seven European countries, the USA and Taiwan. |
T30 | 125-485 | Sentence | denotes | To ensure heterogenicity, participants were selected from various fields of expertise: medical microbiology (PEV, KL, CL-F, TRR), infectious diseases (BJAR, MB, TC, CJC, OAC, DRG, NAFJ, BJK, OL, MH-N, TFP, FLvdV), intensive care medicine (EA, SB, PD, PW-LL, IM-L, JAS, LV, JW), clinical pharmacology (RJMB, RL, IS), public health (TC) and hematology (OAC, JM). |
T31 | 486-653 | Sentence | denotes | Selected participants furthermore had specific expertise in epidemiology, diagnosis and management of invasive fungal diseases or fungal disease guideline development. |
T32 | 654-706 | Sentence | denotes | The meeting was prepared by PEV, RJMB, JW and FLvdV. |
T33 | 707-779 | Sentence | denotes | Case definitions were developed through a process of informal consensus. |
T34 | 780-1115 | Sentence | denotes | Although a systematic literature review was not performed, experts in the field presented overviews regarding epidemiology, pathogenesis, diagnosis and treatment of IAPA, which were followed by a group discussion process designed to allow members of the group to voice their opinions and contribute equally to the decision-making [12]. |
T35 | 1116-1194 | Sentence | denotes | The goal of the consensus process was to bring the group to general agreement. |
T36 | 1195-1380 | Sentence | denotes | Presentations and initial discussions took place on a single day meeting in April 2019 in Amsterdam and were continued through electronic exchange of views until consensus was achieved. |
T37 | 1381-1568 | Sentence | denotes | The chosen framework included host and risk factors, clinical factors and mycological evidence, similar to the framework in the EORTC/MSGERC definitions and the AspICU algorithm [10, 11]. |
T38 | 1569-1662 | Sentence | denotes | A medical writer made notes of the meeting, which were used as input to write the manuscript. |
T39 | 1663-1779 | Sentence | denotes | A first draft manuscript was prepared by PEV, BJAR, RJMB, JW and FLvdV and circulated for comments from all experts. |
T40 | 1780-1833 | Sentence | denotes | The experts reviewed and commented on the manuscript. |
T41 | 1834-1900 | Sentence | denotes | Using these comments, a final version was circulated for approval. |
T42 | 1901-2115 | Sentence | denotes | The logistics of the meeting were handled by a certified Congress organizer (Congress Care, s’Hertogenbosch, the Netherlands) with financial support of Pfizer (Pfizer B.V., Capelle aan den IJssel, the Netherlands). |
T43 | 2116-2286 | Sentence | denotes | Congress Care and Pfizer had no influence on the selection of participants, selected topics, discussions, preparation and final approval of the content of the manuscript. |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T39 | 412-424 | CHEBI:52217;CHEBI:52217 | denotes | pharmacology |
T40 | 597-603 | NCBITaxon:4751 | denotes | fungal |
T41 | 616-622 | NCBITaxon:4751 | denotes | fungal |
T42 | 769-778 | SO:0000993 | denotes | consensus |
T43 | 1132-1141 | SO:0000993 | denotes | consensus |
T68350 | 412-424 | CHEBI:52217;CHEBI:52217 | denotes | pharmacology |
T21985 | 597-603 | NCBITaxon:4751 | denotes | fungal |
T87756 | 616-622 | NCBITaxon:4751 | denotes | fungal |
T42141 | 769-778 | SO:0000993 | denotes | consensus |
T46351 | 1132-1141 | SO:0000993 | denotes | consensus |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32572532-10623041-47963399 | 1111-1113 | 10623041 | denotes | 12 |
32572532-22517788-47963400 | 1564-1566 | 22517788 | denotes | 11 |
T46095 | 1111-1113 | 10623041 | denotes | 12 |
T11193 | 1564-1566 | 22517788 | denotes | 11 |